$VCYT
Veracyte Inc Stock $vcyt

$vcyt Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000143774920016062 Filed on July 30, 2020

Income Statement

Concept	2020 Q2	2019 Q2	2019 Q1
Revenue	$20.70M	$30.14M	$29.53M
YoY Change	-31.3%	32.46%	47.34%
Cost Of Revenue	$7.660M	$8.777M	$8.513M
YoY Change	-12.73%	6.44%	8.21%
Gross Profit	$13.05M	$21.36M	$21.02M
YoY Change	-38.9%	47.25%	72.63%
Gross Profit Margin	63.03%	70.88%	71.17%
Selling, General & Admin	$18.66M	$20.86M	$19.38M
YoY Change	-10.57%	34.12%	12.77%
% of Gross Profit	142.97%	97.68%	92.22%
Research & Development	$4.169M	$3.330M	$3.435M
YoY Change	25.2%	-27.62%	-6.53%
% of Gross Profit	31.95%	15.59%	16.34%
Depreciation & Amortization	$1.960M	$920.0K	$945.0K
YoY Change	113.04%	-7.07%	-3.57%
% of Gross Profit	15.02%	4.31%	4.5%
Operating Expenses	$22.83M	$24.19M	$22.82M
YoY Change	-5.65%	20.03%	9.37%
Operating Profit	-$11.05M	-$3.100M	-$2.067M
YoY Change	256.48%	-47.61%	-76.92%
Interest Expense	$65.00K	$235.0K	$303.0K
YoY Change	-72.34%	-51.14%	-32.37%
% of Operating Profit
Other Income/Expense, Net	$91.00K	$841.0K	$453.0K
YoY Change	-89.18%	460.67%	100.44%
Pretax Income	-$11.03M	-$2.490M	-$1.920M
YoY Change	342.77%	-60.16%	-79.08%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$11.03M	-$2.494M	-$1.917M
YoY Change	342.06%	-60.1%	-79.12%
Net Earnings / Revenue	-53.25%	-8.28%	-6.49%
Basic Earnings Per Share	-$0.22
Diluted Earnings Per Share	-$0.22	-$54.62K	-$46.64K
COMMON SHARES
Basic Shares Outstanding	50.21M shares	41.64M shares	41.11M shares
Diluted Shares Outstanding	50.21M shares

Balance Sheet

Concept	2020 Q2	2019 Q2	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$147.5M	$192.6M	$67.80M
YoY Change	-23.42%	709.24%	149.26%
Cash & Equivalents	$147.5M	$192.6M	$67.84M
Short-Term Investments
Other Short-Term Assets	$2.900M	$2.600M	$2.400M
YoY Change	11.54%	44.44%	14.29%
Inventory	$7.041M	$5.104M	$3.768M
Prepaid Expenses
Receivables	$15.31M	$19.63M	$16.62M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$172.7M	$220.0M	$90.62M
YoY Change	-21.49%	428.28%	92.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.640M	$8.150M	$8.114M
YoY Change	6.01%	-9.8%	-11.95%
Goodwill	$2.725M	$1.057M	$1.057M
YoY Change	157.81%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.271M	$1.061M	$1.049M
YoY Change	19.79%	77.42%	125.11%
Total Long-Term Assets	$84.05M	$32.43M	$32.92M
YoY Change	159.19%	36.1%	36.37%
TOTAL ASSETS
Total Short-Term Assets	$172.7M	$220.0M	$90.62M
Total Long-Term Assets	$84.05M	$32.43M	$32.92M
Total Assets	$256.7M	$252.4M	$123.5M
YoY Change	1.73%	285.54%	73.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.224M	$4.061M	$4.064M
YoY Change	-45.24%	106.98%	21.1%
Accrued Expenses	$9.386M	$9.820M	$8.788M
YoY Change	-4.42%	16.5%	3.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$13.11M	$15.32M	$14.33M
YoY Change	-14.46%	47.44%	21.03%
LONG-TERM LIABILITIES
Long-Term Debt	$801.0K	$585.0K	$12.85M
YoY Change	36.92%	-97.67%	-48.62%
Other Long-Term Liabilities	$16.70M	$12.20M	$12.60M
YoY Change	36.89%	205.0%	207.32%
Total Long-Term Liabilities	$801.0K	$585.0K	$12.85M
YoY Change	36.92%	-97.67%	-48.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.11M	$15.32M	$14.33M
Total Long-Term Liabilities	$801.0K	$585.0K	$12.85M
Total Liabilities	$30.59M	$28.14M	$39.77M
YoY Change	8.72%	-29.05%	-3.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$269.4M	-$238.5M	-$236.0M
YoY Change	12.97%	5.29%	7.15%
Common Stock	$495.6M	$462.7M	$319.8M
YoY Change	7.1%	83.39%	27.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$226.1M	$224.2M	$83.77M
YoY Change
Total Liabilities & Shareholders Equity	$256.7M	$252.4M	$123.5M
YoY Change	1.73%	285.54%	73.53%

Cashflow Statement

Concept	2020 Q2	2019 Q2	2019 Q1
OPERATING ACTIVITIES
Net Income	-$11.03M	-$2.494M	-$1.917M
YoY Change	342.06%	-60.1%	-79.12%
Depreciation, Depletion And Amortization	$1.960M	$920.0K	$945.0K
YoY Change	113.04%	-7.07%	-3.57%
Cash From Operating Activities	-$8.420M	-$2.460M	-$1.011M
YoY Change	242.28%	-20.65%	-86.36%
INVESTING ACTIVITIES
Capital Expenditures	-$640.0K	-$650.0K	$765.0K
YoY Change	-1.54%	22.64%	237.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$20.00K
YoY Change
Cash From Investing Activities	-$640.0K	-$660.0K	-$749.0K
YoY Change	-3.03%	24.53%	229.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$137.8M
YoY Change
Debt Paid & Issued, Net			$12.50M
YoY Change
Cash From Financing Activities	3.390M	127.9M	-$8.394M
YoY Change	-97.35%	53200.0%	-1031.63%
NET CHANGE
Cash From Operating Activities	-8.420M	-2.460M	-$1.011M
Cash From Investing Activities	-640.0K	-660.0K	-$749.0K
Cash From Financing Activities	3.390M	127.9M	-$8.394M
Net Change In Cash	-5.670M	124.8M	-$10.15M
YoY Change	-104.54%	-3781.42%	50.68%
FREE CASH FLOW
Cash From Operating Activities	-$8.420M	-$2.460M	-$1.011M
Capital Expenditures	-$640.0K	-$650.0K	$765.0K
Free Cash Flow	-$7.780M	-$1.810M	-$1.776M
YoY Change	329.83%	-29.57%	-76.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001384101
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50582246
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50446104
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50446104
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49625341
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49625341
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2020Q2	vcyt	Number Of Disease Areas With Genomic Testing NumberOfDiseaseAreasWithGenomicTesting	4	pure
CY2019Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1000000.0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147450000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	159317000	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15306000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19329000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	7041000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6806000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2891000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2235000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	172688000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	187687000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8640000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8933000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3000	USD
	dei	Entity Registrant Name EntityRegistrantName	VERACYTE, INC.
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	62471000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	2725000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1495000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	65019000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	2725000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8339000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8808000	USD
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	603000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	603000	USD
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1271000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1437000	USD
CY2020Q2	us-gaap	Assets Assets	256737000	USD
CY2019Q4	us-gaap	Assets Assets	275212000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2224000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2328000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9386000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13734000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1407000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	13105000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17469000	USD
CY2020Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	801000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	694000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	5948000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	6088000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10736000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11506000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	30590000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	35757000	USD
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	50000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	50000	USD
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	495523000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	486090000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-269426000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-246685000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	226147000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	239455000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	256737000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	275212000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20704000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30136000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51826000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59665000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4169000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3330000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8576000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6765000	USD
CY2020Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10701000	USD
CY2019Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13943000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	28285000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	26420000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7957000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6920000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15770000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13824000	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1273000	USD
CY2019Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	266000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2548000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	533000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23251000	USD
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	31755000	USD
CY2019Q2	us-gaap	Costs And Expenses CostsAndExpenses	33236000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	75077000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	64832000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11051000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3100000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	630000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5167000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	65000	USD
CY2019Q2	us-gaap	Interest Expense InterestExpense	235000	USD
	us-gaap	Interest Expense InterestExpense	120000	USD
	us-gaap	Interest Expense InterestExpense	538000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	91000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	841000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1294000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-11025000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-2494000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22741000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4411000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.45
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50212123
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	45586081
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50002377
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43389540
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	230422000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3764000	USD
CY2020Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	374000	USD
CY2020Q2	vcyt	Adjustments To Additional Paid In Capital Sharebased Compensation Increase For Cost Recognition Employee AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationIncreaseForCostRecognitionEmployee	3009000	USD
CY2020Q2	vcyt	Adjustments To Additional Paid In Capital Sharebased Compensation Increase For Cost Recognition Nonemployee AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationIncreaseForCostRecognitionNonemployee	20000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	331000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-11025000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	226147000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	239455000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4745000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1101000	USD
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2678000	USD
	vcyt	Adjustments To Additional Paid In Capital Sharebased Compensation Increase For Cost Recognition Employee AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationIncreaseForCostRecognitionEmployee	5560000	USD
	vcyt	Adjustments To Additional Paid In Capital Sharebased Compensation Increase For Cost Recognition Nonemployee AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationIncreaseForCostRecognitionNonemployee	20000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	685000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22741000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	226147000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	83772000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	137848000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2668000	USD
CY2019Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	120000	USD
CY2019Q2	vcyt	Adjustments To Additional Paid In Capital Sharebased Compensation Increase For Cost Recognition Employee AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationIncreaseForCostRecognitionEmployee	2334000	USD
CY2019Q2	vcyt	Adjustments To Additional Paid In Capital Sharebased Compensation Increase For Cost Recognition Nonemployee AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationIncreaseForCostRecognitionNonemployee	55000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	177000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-2494000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	224240000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	79755000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	137848000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6908000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	491000	USD
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	676000	USD
	vcyt	Adjustments To Additional Paid In Capital Sharebased Compensation Increase For Cost Recognition Employee AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationIncreaseForCostRecognitionEmployee	3932000	USD
	vcyt	Adjustments To Additional Paid In Capital Sharebased Compensation Increase For Cost Recognition Nonemployee AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationIncreaseForCostRecognitionNonemployee	75000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	318000	USD
	us-gaap	Interest Paid Net InterestPaidNet	319000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6265000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7405000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3171000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147450000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4411000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	119525000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5849000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	224240000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22741000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4411000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3929000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1869000	USD
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-0	USD
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	17000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4325000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	83000	USD
	vcyt	Interest Expense On Endof Term Debt Obligation InterestExpenseOnEndofTermDebtObligation	107000	USD
	vcyt	Interest Expense On Endof Term Debt Obligation InterestExpenseOnEndofTermDebtObligation	120000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	1088000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
	vcyt	Noncash Portion Of Lease Expense NoncashPortionOfLeaseExpense	469000	USD
	vcyt	Noncash Portion Of Lease Expense NoncashPortionOfLeaseExpense	431000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-140000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4023000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6458000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1323000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1702000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	664000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	192000	USD
	vcyt	Increase Decrease In Operating Lease Right Of Use Asset Lease Liability IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiability	682000	USD
	vcyt	Increase Decrease In Operating Lease Right Of Use Asset Lease Liability IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiability	604000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-166000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-25000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	122000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1746000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4343000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1319000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13724000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3466000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1314000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1424000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	17000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1314000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1407000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	137848000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	-0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	24900000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	-0	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	152000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2678000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	676000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11867000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	114652000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	159920000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78598000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148053000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	159920000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148053000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	193250000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	72000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	159317000	USD
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	603000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	603000	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i><b>Reclassifications</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Certain prior period balances have been reclassified to conform to current period presentation of the Company’s condensed consolidated financial statements and accompanying notes. Such reclassifications have <em style="font: inherit;">no</em> effect on previously reported results of operations, retained earnings or consolidated balance sheet totals; however, for the period ended <em style="font: inherit;"> June 30, 2019</em>, the Company reclassified $431,000 of changes in operating assets and liabilities to noncash lease expense in the statement of cash flows.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Use of Estimates</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The preparation of unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Items subject to such estimates include: revenue recognition; write-down of supplies; the useful lives of property and equipment; the recoverability of long-lived assets; the incremental borrowing rate for leases; the estimation of the fair value of intangible assets and contingent consideration; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; reserve on accounts receivable and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenue and expenses that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates and assumptions.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p>
CY2019Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6325000
CY2019Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	23.25
CY2019Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	137800000	USD
CY2019Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9200000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Concentrations of Credit Risk and Other Risks and Uncertainties</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The worldwide spread of coronavirus, or COVID-<em style="font: inherit;">19,</em> has created significant uncertainty in the global economy. There have been <em style="font: inherit;">no</em> comparable recent events that provide guidance as to the effect the spread of COVID-<em style="font: inherit;">19</em> as a global pandemic <em style="font: inherit;"> may </em>have, and, as a result, the ultimate impact of COVID-<em style="font: inherit;">19</em> and the extent to which COVID-<em style="font: inherit;">19</em> impacts the Company’s business, results of operations and financial condition will depend on future developments, which are highly uncertain and difficult to predict. If the financial markets or the overall economy are impacted for an extended period, the Company’s liquidity, revenues, supplies, goodwill and intangibles <em style="font: inherit;"> may </em>be adversely affected</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The majority of the Company’s cash and cash equivalents are deposited with <em style="font: inherit;">one</em> major financial institution in the United States. Deposits in this institution <em style="font: inherit;"> may </em>exceed the amount of insurance provided on such deposits. The Company has <em style="font: inherit;">not</em> experienced any losses on its deposits of cash and cash equivalents.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Several of the components of the Company’s sample collection kits and test reagents, and its nCounter Analysis System and related diagnostic kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company’s requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company is also subject to credit risk from its accounts receivable related to its sales. Credit risk for accounts receivable from testing revenue is incorporated in testing revenue accrual rates as the Company assesses historical collection rates and current developments to determine accrual rates and amounts the Company will ultimately collect. The Company generally does <em style="font: inherit;">not</em> perform evaluations of customers’ financial condition for testing revenue and generally does <em style="font: inherit;">not</em> require collateral. The Company assesses credit risk and the amount of accounts receivable the Company will ultimately collect for product, biopharmaceutical and collaboration revenue based on collection history, current developments and credit worthiness of the customer. The estimate of credit losses is <em style="font: inherit;">not</em> material at <em style="font: inherit;"> June 30, 2020</em>.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Through <em style="font: inherit;"> June 30, 2020</em>, most of the Company’s revenue has been derived from the sale of Afirma. To date, Afirma has been delivered primarily to physicians in the United States. The Company’s <em style="font: inherit;">third</em>-party payers and other customers in excess of <em style="font: inherit;">10%</em> of total revenue and their related revenue as a percentage of total revenue were as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Three Months Ended June 30,</b></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Six Months Ended June 30,</b></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2020</b></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2019</b></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2020</b></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2019</b></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Medicare</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Johnson and Johnson Services, Inc.</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">UnitedHealthcare</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">33</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">47</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">Less than <em style="font: inherit;">10%</em></sup></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company’s <em style="font: inherit;">third</em>-party payers and other customers in excess of <em style="font: inherit;">10%</em> of accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows at the following dates:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">June 30, 2020</em></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31, 2019</em></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Johnson and Johnson Services, Inc.</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Medicare</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">*Less than 10%</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p>
CY2020Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5795658
CY2019Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6503879
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5756805
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6370306
CY2020Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6703000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10100000	USD
CY2020Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2683000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3634000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9386000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13734000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1175000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2401000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2472000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2543000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2614000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4227000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15432000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3201000	USD
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	12231000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1495000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10736000	USD
CY2020Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1000000.0	USD
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5534822
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5562484
CY2020Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8854709
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7690456

Files In Submission

Name	View Source	Status
0001437749-20-016062-index-headers.html	Edgar Link	pending
0001437749-20-016062-index.html	Edgar Link	pending
0001437749-20-016062.txt	Edgar Link	pending
0001437749-20-016062-xbrl.zip	Edgar Link	pending
ex_185665.htm	Edgar Link	pending
ex_185666.htm	Edgar Link	pending
ex_185667.htm	Edgar Link	pending
ex_185668.htm	Edgar Link	pending
ex_194729.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vcyt-20200630.xsd	Edgar Link	pending
vcyt-20200630_cal.xml	Edgar Link	unprocessable
vcyt-20200630_def.xml	Edgar Link	unprocessable
vcyt-20200630_lab.xml	Edgar Link	unprocessable
vcyt-20200630_pre.xml	Edgar Link	unprocessable
vcyt20200630_10q.htm	Edgar Link	pending
vcyt20200630_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VCYT
Veracyte Inc Stock $vcyt

2020 Q2 Form 10-Q Financial Statement

#000143774920016062 Filed on July 30, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCYT Veracyte Inc Stock $vcyt

2020 Q2 Form 10-Q Financial Statement

#000143774920016062 Filed on July 30, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCYT
Veracyte Inc Stock $vcyt